Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: implications for clinical trials.
about
Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeuticsCurrent and Future Gene Therapy for Malignant GliomasTherapeutic angiogenesis for cardiovascular diseaseCell Penetrating Peptide Conjugated Chitosan for Enhanced Delivery of Nucleic AcidHMGB1 mediates endogenous TLR2 activation and brain tumor regressionIn vivo polarization of IFN-gamma at Kupfer and non-Kupfer immunological synapses during the clearance of virally infected brain cells.Antitumor activity and prolonged expression from a TRAIL-expressing adenoviral vector.In vivo transgene expression from an adenoviral vector is altered following a 6-OHDA lesion of the dopamine system.Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials.T cells' immunological synapses induce polarization of brain astrocytes in vivo and in vitro: a novel astrocyte response mechanism to cellular injury.Kupfer-type immunological synapse characteristics do not predict anti-brain tumor cytolytic T-cell function in vivo.Uncertainty in the translation of preclinical experiments to clinical trials. Why do most phase III clinical trials fail?Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safety.Gene therapy in the CNS.A novel bicistronic high-capacity gutless adenovirus vector that drives constitutive expression of herpes simplex virus type 1 thymidine kinase and tet-inducible expression of Flt3L for glioma therapeuticsGene transfer into rat brain using adenoviral vectors.Brain-specific expression of an exogenous gene after i.v. administration.Marmosets as a preclinical model for testing "off-label" use of doxycycline to turn on Flt3L expression from high-capacity adenovirus vectors.Nonneurotropic adenovirus: a vector for gene transfer to the brain and gene therapy of neurological disordersLentiviral-induced high-grade gliomas in rats: the effects of PDGFB, HRAS-G12V, AKT, and IDH1-R132H.Study of the efficacy, biodistribution, and safety profile of therapeutic gutless adenovirus vectors as a prelude to a phase I clinical trial for glioblastoma.Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model.Molecular advances to treat cancer of the brain.Tomato thymidine kinase-based suicide gene therapy for malignant glioma--an alternative for Herpes Simplex virus-1 thymidine kinase.Adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of recurrent high-grade glioma.Inflammatory and anti-glioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): treatment with hsFlt3L inhibits intracranial glioma progression.Immunomodulatory gene therapy for haematological malignancies.Surface modification of TPGS-b-(PCL-ran-PGA) nanoparticles with polyethyleneimine as a co-delivery system of TRAIL and endostatin for cervical cancer gene therapy.Differentiation and transcription factor gene therapy in experimental parkinson's disease: sonic hedgehog and Gli-1, but not Nurr-1, protect nigrostriatal cell bodies from 6-OHDA-induced neurodegeneration.All in the head: obstacles for immune rejection of brain tumours.Fms-like tyrosine kinase 3 ligand recruits plasmacytoid dendritic cells to the brain.Gene therapy and targeted toxins for glioma.Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: toward realistic long-term neurological gene therapy for chCombined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen.The Trojan Horse Liposome Technology for Nonviral Gene Transfer across the Blood-Brain BarrierOptimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitro.Immune-mediated loss of transgene expression from virally transduced brain cells is irreversible, mediated by IFNγ, perforin, and TNFα, and due to the elimination of transduced cellsTargeted toxins for glioblastoma multiforme: pre-clinical studies and clinical implementation.In vivo mature immunological synapses forming SMACs mediate clearance of virally infected astrocytes from the brainTyrosine hydroxylase replacement in experimental Parkinson's disease with transvascular gene therapy.
P2860
Q24616751-269BC3AD-2FDD-419A-AC4E-B2184B450D35Q24792748-26F1A9D9-34F9-462D-B438-8367986ED6B8Q24799337-A87C3EE7-7E91-4A6E-82F8-DDD943EBCFB6Q26774462-625E411C-11F2-4360-88AD-4B761ED05854Q27307459-CDA05F3B-57C4-448F-A640-511346D0C109Q30485565-786B9749-1D45-4F06-845B-7FF0280B3E51Q31087174-45DAEA9C-222A-40EF-A203-6636D89CEC5AQ33216908-FEC163C3-0FCC-457D-8B56-32ED9D0746F5Q33330270-C1FB11D0-7BD1-47E5-A7E1-295B70B3026CQ33361577-F63B5452-857E-4A05-BB91-DAA198513B5EQ33740759-9FDEB623-C129-49D8-B1CE-011943FE7B22Q33828102-6EAFDC66-A560-4F38-A714-DA67180D29D2Q33828114-BE8FC5E6-266C-423A-848A-77271CC21821Q33837123-EE56A0B5-07BF-4020-8FC6-74BC9897E836Q33877450-54EB7647-9785-4BF4-8958-BAE91B9083D2Q33904294-5C2E362A-F5B9-46CC-8D81-0EAA3ECC0A22Q33948080-9808530B-4564-4071-AA59-7CA219B816C4Q33950709-5FB7D7C6-6D26-4B59-95F2-F25E5D271322Q33985663-5AF2ABEB-A7FB-458D-BB2C-BA31A11CB8EEQ34000761-5586B6B3-9808-4F13-BF2B-2BB8041B0470Q34012284-656510DD-741D-46E6-AEE1-BD30E16D3E3AQ34063140-0CED8CD7-D72E-467B-82C8-368A0E4B48D6Q34074888-A382303F-CB18-497B-9A35-6EED0636C018Q34459264-35DFDC86-83ED-4BAF-BC03-327C6A557886Q34506962-5D6478C0-C590-4718-8D67-F08017F52968Q34546483-6E176A4F-4603-45D7-8571-9B103AB61657Q34579664-F68607EC-FCEF-4074-8DEF-D6E68CE37AA1Q34660767-7BF2D4CA-89DE-4E47-AED9-9FF7E136CC5DQ34684014-9C4D60DE-438C-4155-9FAE-F73623A144EFQ34842204-B7AC691C-D15E-486D-B0F4-DAB522768C57Q35069546-C42F95E4-F9FC-4D8D-A156-196847DE0984Q35118933-9E15B8EC-3785-4122-A6D4-7AC74A1AA4F2Q35161530-AF64680F-92C2-4C6A-80FC-328DE1006EFBQ35285859-39EE9322-E448-4CDA-89BD-A113DE111A12Q35585191-90E340B4-6E9C-4DE9-B7B0-6E67031FEC16Q35870480-16D6D400-79D0-4A13-BB3B-B130CD6CCEF6Q35876228-61FA66D1-BC18-429C-B2A8-16DD8C7CCC79Q35999648-05B33D05-F90D-4BB9-B41E-FE0D7D9D453FQ36019340-47CBE306-6681-4109-BDA1-1F33172B976BQ36045429-D238BBAE-49AC-4AB6-99B2-B8586D25EDD4
P2860
Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: implications for clinical trials.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
Chronic brain inflammation and ...... lications for clinical trials.
@en
type
label
Chronic brain inflammation and ...... lications for clinical trials.
@en
prefLabel
Chronic brain inflammation and ...... lications for clinical trials.
@en
P2093
P2860
P921
P356
P1433
P1476
Chronic brain inflammation and ...... lications for clinical trials.
@en
P2093
Bolognani F
Cowsill CM
Klatzmann D
Löwenstein PR
Morrissey G
Southgate TD
P2860
P2888
P304
P356
10.1038/15207
P407
P577
1999-11-01T00:00:00Z